These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 31127357

  • 1. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.
    Zhou J, Gou Z, Wu R, Yuan Y, Yu G, Zhao Y.
    Skeletal Radiol; 2019 Dec; 48(12):1915-1924. PubMed ID: 31127357
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Dec; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis.
    Shen G, Deng H, Hu S, Jia Z.
    Skeletal Radiol; 2014 Nov; 43(11):1503-13. PubMed ID: 24841276
    [Abstract] [Full Text] [Related]

  • 4. Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer.
    Zacho HD, Nielsen JB, Afshar-Oromieh A, Haberkorn U, deSouza N, De Paepe K, Dettmann K, Langkilde NC, Haarmark C, Fisker RV, Arp DT, Carl J, Jensen JB, Petersen LJ.
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1884-1897. PubMed ID: 29876619
    [Abstract] [Full Text] [Related]

  • 5. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
    Lin CY, Lee MT, Lin CL, Kao CH.
    Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999
    [Abstract] [Full Text] [Related]

  • 6. 18F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies.
    Sheikhbahaei S, Jones KM, Werner RA, Salas-Fragomeni RA, Marcus CV, Higuchi T, Rowe SP, Solnes LB, Javadi MS.
    Ann Nucl Med; 2019 May; 33(5):351-361. PubMed ID: 30877561
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 12. 99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer.
    Wondergem M, van der Zant FM, Knol RJJ, Burgers AMG, Bos SD, de Jong IJ, Pruim J.
    World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
    [Abstract] [Full Text] [Related]

  • 13. Head-To-Head Comparison of 68Ga-PSMA-11 PET/CT and 99mTc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A Meta-Analysis.
    Zhao G, Ji B.
    AJR Am J Roentgenol; 2022 Sep; 219(3):386-395. PubMed ID: 35441529
    [Abstract] [Full Text] [Related]

  • 14. [Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer].
    Garcia JR, Moreno C, Valls E, Cozar P, Bassa P, Soler M, Alvarez-Moro FJ, Moragas M, Riera E.
    Rev Esp Med Nucl Imagen Mol; 2015 Sep; 34(3):155-61. PubMed ID: 25443648
    [Abstract] [Full Text] [Related]

  • 15. Prospective comparative study of 18F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer.
    Fonager RF, Zacho HD, Langkilde NC, Fledelius J, Ejlersen JA, Hendel HW, Haarmark C, Moe M, Mortensen JC, Jochumsen MR, Petersen LJ.
    Acta Oncol; 2018 Aug; 57(8):1063-1069. PubMed ID: 29447047
    [Abstract] [Full Text] [Related]

  • 16. Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy.
    Uprimny C, Svirydenka A, Fritz J, Kroiss AS, Nilica B, Decristoforo C, Haubner R, von Guggenberg E, Buxbaum S, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
    [Abstract] [Full Text] [Related]

  • 17. Direct comparison of choline PET/CT and MRI in the diagnosis of lymph node metastases in patients with prostate cancer.
    Huang SM, Yin L, Yue JL, Li YF, Yang Y, Lin ZC.
    Medicine (Baltimore); 2018 Dec; 97(50):e13344. PubMed ID: 30557983
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 68Ga-PSMA PET/CT for the evaluation of metastasis in patients with prostate cancer: A systematic review and meta-analysis.
    Zhou J, Wu R, Wang W, Zhao Y, Liu X.
    Hell J Nucl Med; 2022 Dec; 25(3):297-311. PubMed ID: 36576728
    [Abstract] [Full Text] [Related]

  • 20. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
    Caglar M, Tuncel M, Yildiz E, Karabulut E.
    Ann Nucl Med; 2020 Dec; 34(12):932-941. PubMed ID: 32975741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.